Merck's eye disease drug meets main goal in trial
Merck NYSE:MRK said on Thursday its drug met the main goal in a mid- to late-stage trial testing it in adult patients with a type of disease that affects blood vessels at the back of the eye.
Merck NYSE:MRK said on Thursday its drug met the main goal in a mid- to late-stage trial testing it in adult patients with a type of disease that affects blood vessels at the back of the eye.